Nothing special, but kinda priceless no? 😁

Been doing divide and conquer for lens fragmentation. Finding I get into the situation where I end up pushing down on the capsule while trying to divide the nucleus.

Have cognitively tried to lift while moving the phaco probe and 2nd instrument apart but somehow the vector still ends up downwards. The groove is deep enough usually.

Any tips to improve?

For those who did residency, eg in Europe, with close to no surgical experience- how did you get that first opportunity to operate?

Any junior cataract fellowship that I can apply for? Everywhere i go seems to be looking for someone with cataract surgery experience.

Hey all,

Fresh pgy2 here. Been doing lots of intravitreals with subconj lido. I cause subconj heme in ~80% of my patients. Would appreciate tips on how to improve.

Right now I angle the needle bevel up and anteriorly away from the cornea and attempt to barely graze the conj before infiltrating. Patients dont feel the actual injection, but its kinda bummer to see them after with red, bloody eyes.

Thank you!

The FDA target action date for Outlook Therapeutics' Lytenava (ONS-5010 / bevacizumab-vikg) is set for July 29, 2026.

If approved, it becomes the first FDA-sanctioned ophthalmic formulation of bevacizumab specifically indicated for wet AMD.

About 2.7 million off-label compounded Avastin injections are administered annually in the US. Approval of an on-label alternative introduces significant operational shifts:

1.Compounding & Safety: Eliminates dependence on compounding pharmacies and risks around silicone oil droplets or batch contamination.

1. Payer Mandates: Expect commercial payers and Medicare Advantage plans to enforce strict step-therapy policies, requiring Lytenava before approving higher-cost anti-VEGF agents (Vabysmo, Eylea HD).

2. Practice Economics: Moves clinics from low-margin off-label compounded syringes toward standard ASP+6% buy-and-bill models.

For those colleagues in active practice or med leadership:

How is your institution or clinic preparing for this?

Do you anticipate payers completely pulling coverage for repackaged cancer-label Avastin once an on-label option is available?

https://www.managedhealthcareexecutive.com/view/fda-sets-goal-date-for-ophthalmic-version-of-bevacizumab